| Active substance | Avacopan |
| Holder | Vifor Fresenius Medical Care Renal Pharma Ltd. |
| Status | closed |
| Indication | in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 03/11/2025 |